Cupid Ltd Q3 FY2024 Concall Summary

Key Takeaways

• A quarter of two halves: Revenue hit ₹40 Cr (+16% QoQ) but female condom sales collapsed to ₹1 Cr after a South Africa lab breakdown, creating a ₹23 Cr inventory overhang.
• The order book is the real story: Management disclosed ₹103 Cr+ in expected orders (South Africa, Brazil, UNFPA, GoI) for delivery over the next 12 months, a signal that dwarfs the soft quarterly print.
• Balance sheet is being weaponized for growth: A ₹385 Cr fundraise, bonus issue, share split, land acquisition and an active hunt for an overseas non-latex condom manufacturer all landed this quarter, pointing to a management that is building for scale, not optimizing the present.
• Retail is a tiny, patient experiment: The network reached 1,000 outlets in North India from mid-December but management refuses to guide revenue or set a scaling timeline, wanting to see traction first.
• What to watch next quarter: Whether the ₹50-55 Cr Q4 topline guide materializes, any concrete movement on the overseas acquisition, and the pace of inventory days reduction from the current 200+ level.

The Female Condom Disruption

• Root cause: A major breakdown in laboratory apparatus in South Africa halted exports, slashing female condom sales to just ₹1 Cr in Q3. Material stockpiled at the Nasik factory, pushing inventory to ₹23 Cr.
• Recovery path: Management expects female condom sales to rebound to ~₹21 Cr in Q4 FY24, implying the lab issue is resolved or close to it.
• Inventory overhang: Inventory days have run north of 200 for three years, partly because premium condom inventory was stuck. Management targets a 20% improvement, a reduction of roughly 40-45 days, by improving supplier terms and pushing non-UNFPA distributors on payment cycles.

Omprakash Garg: "The study is going rather slowly in South Africa. And also our discussions with the USFDA are still going on. They have raised many new questions which we are in the process of replying."

The Order Book & Revenue Visibility

• Near-term pipeline: Management disclosed significant expected orders for February-March: South Africa (~₹50 Cr), Brazil (~₹23 Cr), Government of India (~₹10 Cr additional), and UNFPA (~₹30 Cr for Q1 FY25), all for delivery over the next 12 months.
• Q4 guide divergence: CFO Omprakash Garg guided ₹50-55 Cr topline for Q4, while promoter Aditya Halwasiya offered ₹60-65 Cr, a gap management did not reconcile on the call.
• Export dependence: 89% of Q3 sales were exports, with only 11% domestic split between B2C sales and IVD kits, making the business highly sensitive to international order flow and tender cycles.

Fundraising & Capital Structure Reset

• ₹385 Cr preferential issue to FIIs: Funds to be received within 18 months; a very small portion earmarked for working capital, with the bulk aimed at a strategic overseas acquisition.
• Shareholder-friendly moves: A bonus issue and a 10-to-1 share split were announced alongside the fundraise, improving liquidity and accessibility.
• ESOP redistribution: Existing warrant holders agreed to surrender 50% of their issuance so ESOPs could be granted to more key managerial personnel, with no promoters participating. The exercise price of ₹140 was set in August 2022 and management explicitly ruled out changing it.

Aditya Halwasiya: "The board who issued the ESOP, which Mr. Om Garg was a part of, decided an exercise price of Rs. 140 and post that we don't want to change the ESOP in any way shape or form because there's been no material change in the company on the day-to-day functioning."

The Overseas Acquisition Thesis

• What Cupid wants: A manufacturing setup, not a brand, located outside India, likely in Asia, that adds polyisoprene (PI) and polyurethane (PU) condom capability to its current latex-only portfolio.
• Why it matters: No Indian manufacturer makes PI or PU condoms; they are imported. The acquisition would also give faster regulatory approvals for the IVD segment.
• India is not the near-term market: PI/PU condoms are minuscule in India due to price sensitivity; management sees a domestic shift toward such materials only in 10-15 years. The target market is other Asian countries where PI/PU condoms already sell: Malaysia, China, Thailand, Indonesia.
• Timeline opacity: Management declined to give any specific timeline or acquisition size, and refused to name the target company, calling the process active but uncommitted.

Aditya Halwasiya: "We will be looking to buy a manufacturing setup rather than the brand."

Retail: A Cautious Experiment

• Current state: Distribution began mid-December, reaching 1,000 outlets primarily in Northern India as a test market, with a pan-India sales team of zonal managers, area managers and sales executives now in place.
• No revenue guidance: Management explicitly stated retail is not guiding revenue in any significant way and declined to share repeat rates or per-store ticket sizes when asked.
• Scaling philosophy: The company will not spend aggressively or set a scaling timeline until it sees good traction from the current 1,000 stores, a posture management described as avoiding being "unconvoluted" with spending.
• Product bundling in the works: Formulations are ready to bundle deodorant sprays with existing condom products, adding a potential basket-size lever when retail does scale.

Capacity, Approvals & the Medium-Term Bet

• Capacity expansion: 3-4 new dipping lines to be introduced by end of 2024, adding close to 30 crore units of male condom capacity. Post-expansion, management expects topline close to ₹400 Cr with EBITDA upwards of ₹100 Cr.
• USFDA pathway is slow and uncertain: The female condom study in South Africa is progressing slowly; the USFDA has raised new questions about conducting part of the study in the US with US participants, which would be very expensive. Management sees positive results as roughly 1-1.5 years away, possibly in FY26.
• IVD certifications: CE Mark and WHO certifications for IVD kits are targeted in 2-3 years, with domestic state-level tender participation possible between September 2024 and May 2025, and African/Latin American country participation after three years of manufacturing experience by May 2025.
• Margin ambition: Management is targeting PAT margins above 25% and EBITDA margins above 35%, though no timeline was attached to these goals.

Aditya Halwasiya: "Looking to get our PAT margins up over and above 25%. And our EBITDA margins will be, it will be better if we keep it above 35%."

Guidance & Commitments

Key Metrics